Læknablaðið - 15.05.1992, Qupperneq 23

LÆKNABLAÐIÐ
179
14. Fielding CJ, Shore VG, Fielding PE. A protein
cofactor of lecithin: cholesterol acyl transferase.
Biochem Biophys Res Commun 1972; 46: 1493-8.
15. Fielding CJ, Fielding PE. Evidence for a lipoprotein
carrier in human plasma catalysing sterol efflux from
cultured fibroblasts and its relationship to lecithin:
cholesterol acyl transferase. Proc Natl Acad Sci USA
1981; 6: 3911-4.
16. Graham DL, Oram JF. Identification and
characterization of a high density lipoprotein-binding
protein in cell membranes by ligand blotting. J Biol
Chem 1987; 262: 7439-42.
17. Schmitz G, Williamson E. High-density lipoprotein
metabolism, reverse cholesterol transport and
membrane protection. Current Opinion in Lipidology
1991; 2; 177-89.
18. Eaton DL, Fless GM, Kohr WJ, et al. Partial amino
acid sequence of apolipoprotein(a) shows that it is
homologous to plasminogen. Proc Natl Acad Sci
USA 1987; 84: 3224-8.
19. Scanu AM. Lipoprotein (a). A potential bridge
between the fields of atherosclerosis and thrombosis.
Arch Pathol Lab Med 1988; 112: 1045-7.
20. Utermann G, Menzel HJ, Kraft HG, Duba HC,
Kemmler MG, Seitz C. Lp(a) glycoprotein
phenotypes: inheritance and relations to Lp(a)
concentrations in plasma. J Clin Invest 1987; 80:
150-7.
21. Rosengren A, Wilhelmsen L, Eriksson E, Risberg
B, Wedel H. Lipoprotein (a) and coronary heart
disease: a prospective case-control study in a general
population sample of middle aged men. Br Med J
1990; 301: 1248-51.
22. Laufey Steingrímsdóttir, Hólmfríður Þorgeirsdóttir,
Stefanía Ægisdóttir. Könnun á mataræði
Islendinga 1990. 1. Helstu niðurstöður. Rannsóknir
Manneldisráð Islands III. Reykjavík: Manneldisráð
íslands, 1991.
23. Friedewald WT, Levy RI, Fredrickson DS.
Estimation of the concentration of low-density
lipoprotein cholesterol in plasma, without use of the
preperative ultracentrifuge. Clin Chem 1972; 18: 499-
502.
24. Elín Olafsdóttir, Þorvaldur Veigar Guðmundsson.
Samanburður á blóðfitumælingum átta íslenskra
rannsóknastofa. Læknablaðið 1990; 76: 307-11.
25. Naito HK. Reliability of lipid, lipoprotein, and
apolipoprotein measurements. Clin Chem 1988; 34:
B84-B94.
26. Marcovina SM, Albers JJ. Intemational federation
of clinical chemistry study on the standardization
of apolipoproteins A-I and B. Current Opinion in
Lipidology 1991; 2: 355-61.
27. Marti B, Suter E, Riesen WF, Tschopp A, Wanner
HU. Anthropometric and lifestyle correlates of seram
lipoprotein and apolipoprotein levels among normal
non-smoking men and women. Atherosclerosis 1989;
75: 111-22.
28. Assmann G, Schmitz G, Funke H. Analytical
procedures for the differential diagnosis of the
disorders of lipid metabolism. In: Assmann G, ed.
Lipid Metabolism Disorders and Coronary Heart
Disease. Miinchen: MMV Medizin Verlag, 1989.
29. Stampfer MJ, Sacks FM, Salvini S, Willett WC,
Hennekens CH. A prospective study of cholesterol,
apolipoproteins, and the risk of myocardial infarction.
N Engl J Med 1991; 325: 373-81.
30. Wilson WF, Abbott RD, Castelli WP. High
density lipoprotein cholesterol and mortality. The
Framingham Heart Study. Arteriosclerosis 1988; 8:
737-41.
31. Avogaro P, Cazzolato G, Bittolo B, Belussi F,
Quinci GB. Values of apo-AI and apo-B in humans
according to age and sex. Clin Chim Acta 1979; 95:
311-5.
32. Noma A, Hata Y, Goto Y. Quantitation of serum
apolipoprotein A-I, A-II, B, C-II, C-III and E in
healthy Japanese by turbidimetric immunoassey:
reference values, and age- and sex-related
differences. Clin Chim Acta 1991; 199: 147-58.
33. Glueck CJ, McCray C, Speirs J. Measurement
of seram apo A1 and apo B: comparison of
immunoturbidimetric and rate nephelometric
techniques. Clin Chim Acta 1991; 197: 123-32.
34. Puchois P, Kandoussi A, Fievet P, et al.
Apolipoprotein A-I containing lipoproteins in
coronary artery disease. Atherosclerosos 1987; 68:
35-40.
35. Rubin EM, Krauss RM, Spangler EA, Verstuyft
JG, Clift SM. Inhibition of early atherogenesis in
transgenic mice by human apolipoprotein AI. Nature
1991; 353: 265-7.
36. Sandholzer C, Hallman DM, Saha N, Sigurdsson
G, et al. Effects of the apolipoprotein (a) size
polymorphism on the lipoprotein (a) concentration
in 7 ethnic groups. Hum Genet 1991; 86: 607-14.
37. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar
D. Apolipoproteins (a), AI, and B and parental
history in men with early onset ischaemic heart
disease. Lancet 1988; 1: 1070-3.
38. Scanu AM. Lipoprotein (a) as a cardiovascular risk
factor. Trends Cardiovasc Med 1991; 1: 294-9.
39. Hajjar KA, Gavish D, Breslow JL, Nachman RL.
Lipoprotein (a) modulation of endothelial cell surface
fibrinolysis and its potential role in atherosclerosis.
Nature 1989; 339: 303-5.
40. Kostner GM, Bihari-Varga M. Is the atherogenicity
of Lp (a) caused by its reactivity with proteoglycans?
Eur Heart J 1990; 11/Supp. E: 184-9.